July 08, 2020
As per the report titled ’ Global Invasive Fungal Infection (IFI) Market - Analysis By Disease Type, Pipeline Drugs, By Region, By Country (2020 Edition): Market Insight, Competition and Forecast (2019-2024)’, available with Market Study Report LLC, global invasive fungal infection (IFI) market was valued at USD 6103.5 million in the year 2018, and is poised to garner immense traction over 2019-2024.
Increasing pervasiveness of HIV/AIDS, advancements in drugs and facilities provided by hospitals in ICUs, upsurge in chemotherapy, rising use of broad-spectrum antibiotics, and widespread economic growth are slated to propel the market growth. Additionally, demand for reasonably priced products and usage of broad-spectrum antibiotics which makes fungi resistant to antibiotics, and opting for low-cost medicines which are effective for a longer time is further projected to stimulate market expansion.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2459407/
Numerous companies are offering a wide range of antibiotics which has decreased the resistance of medicines, in turn, increasing the risk of fungal infection. Also, increasing investments by major manufacturers to develop low-cost products coupled with favorable government initiatives regarding spreading awareness on the measure taken in an ICU are anticipated to boost the market outlook in the approaching years.
The well-established companies operating in global invasive fungal infection (IFI) market are F2G- The Rare Fungal Disease Company, Cidara, Basilea Pharmaceutica, Bayer AG, GlaxoSmith Kline, Abott, Astellas Pharma Inc., Merck & Co., Pfizer, and Scynexis Inc. among others.